Table 3.
Efficacy of lenvatinib in patients with uHCC
| LEN monotherapy (n = 39) |
LEN combination (n = 72) | LEN + PD1 (n = 30) | LEN + HAIF/TACE (n = 24) | LEN + PD1 + HAIF/TACE (n = 16) | |
|---|---|---|---|---|---|
| CR | 0 | 2/3% | 1/3% | 0 | 0 |
| PR | 6/15% | 19/26% | 10/33% | 7/29% | 2/13% |
| SD | 21/54% | 42/58% | 12/40% | 17/71% | 12/75% |
| ORR | 15% | 29% | 36% | 29% | 13% |
| DCR | 69% | 87% | 76% | 100% | 88% |
Data are presented as n/%
LEN, lenvatinib; PD-1, programmed cell death protein-1 targeted immunotherapy; HAIF, hepatic arterial infusion with drug filtration; TACE, transcatheter arterial chemoembolization; CR, complete response; ORR, objective response rate; DCR, disease control rate; PR, partial response; SD, stable disease